BullFrog AI Holdings, Inc.
BFRG Nasdaq Pharmaceutical Preparations Financials FY2021βFY2025
What BullFrog AI Holdings, Inc. does
No business description yet.
- Legal name
- BullFrog AI Holdings, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 19, 2026
- Accession Β· CIK
- 0001493152-26-011644
0001829247
Revenue and margins
BullFrog AI Holdings, Inc. had $0.1M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
BullFrog AI Holdings, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 25.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably BullFrog AI Holdings, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.0M | $0.1M | $2.6M | $5.4M | $2.2M |
| Debt incl. finance leases | $0.0M | β | β | β | β |
| Interest coverage | β13.7x | β7.1x | β67.9x | β397.6x | β1,177.6x |
| Current ratio | 0.0x | 0.0x | 15.0x | 9.4x | 3.8x |
| Quick ratio | 0.0x | 0.0x | 15.0x | 9.4x | 3.8x |
| Total assets | $0.0M | $0.1M | $2.8M | $5.6M | $2.8M |
| Total liabilities | $1.0M | $3.1M | $0.2M | $0.6M | $0.7M |
| Shareholders' equity | β$1.0M | β$3.1M | $2.6M | $5.0M | $2.1M |
| Net debt (β = net cash) | $0.0M | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 2 / 8 | β / 6 | β / 6 |
| Accruals ratio | β2,034.0% | β4,185.0% | 45.2% | β33.2% | β23.3% |
| Altman Z'' | β1,556.73 | β634.74 | β3.57 | β3.90 | β35.01 |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | β | $0.0M | $0.1M | β | $0.1M |
| Gross profit | β | $0.0M | $0.1M | β | $0.0M |
| Research and development | $0.0M | $0.6M | $1.4M | $2.2M | $1.8M |
| Operating income | β$0.6M | β$2.5M | β$5.4M | β$7.2M | β$6.6M |
| Interest expense | $0.0M | $0.3M | $0.1M | $0.0M | $0.0M |
| Net income | β$0.6M | β$2.8M | β$5.4M | β$7.0M | β$6.5M |
| Net income to common | β | β | β$5.4M | β$7.0M | β$6.5M |
| Diluted EPS | β | β$0.70 | β$0.89 | β$0.85 | β$0.63 |
| Diluted shares | β | 0.00B | 0.01B | 0.01B | 0.01B |
| Cash flow | |||||
| Cash from operations | β$0.4M | β$0.9M | β$6.0M | β$5.6M | β$5.5M |
| Capital expenditure | β | $0.0M | β | β | β |
| Free cash flow | β | β$0.9M | β | β | β |
| Depreciation and amortization | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.1M | $0.3M | $0.6M | $0.9M | $1.0M |
| Balance sheet | |||||
| Cash and short-term investments | $0.0M | $0.1M | $2.6M | $5.4M | $2.2M |
| Total debt | $0.0M | β | β | β | β |
| Current assets | $0.0M | $0.1M | $2.8M | $5.5M | $2.6M |
| Current liabilities | $1.0M | $3.1M | $0.2M | $0.6M | $0.7M |
| Property and equipment, net | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $0.0M | $0.1M | $2.8M | $5.6M | $2.8M |
| Total liabilities | $1.0M | $3.1M | $0.2M | $0.6M | $0.7M |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$1.0M | β$3.1M | $2.6M | $5.0M | $2.1M |
| Margins | |||||
| Gross margin | β | 92.0% | 92.0% | β | 18.8% |
| Operating margin | β | β24,558.0% | β8,257.7% | β | β5,650.9% |
| EBITDA margin | β | β24,548.0% | β8,255.1% | β | β5,649.4% |
| Net margin | β | β28,025.0% | β8,239.8% | β | β5,568.2% |
| FCF margin | β | β9,196.0% | β | β | β |
| Returns | |||||
| Return on capital employed | 55.0% | 80.3% | β207.1% | β145.8% | β308.7% |
| Return on equity | β | β | β | β185.1% | β183.0% |
| Return on assets | β5,858.0% | β6,200.2% | β374.9% | β167.9% | β155.5% |
| Return on tangible equity | β | β | β206.6% | β141.8% | β304.2% |
| Growth | |||||
| Revenue growth | β | β | 550.0% | β | β |
| Share count change | β | β | 50.9% | 36.3% | 25.4% |
| Financial health | |||||
| Interest coverage | β13.7x | β7.1x | β67.9x | β397.6x | β1,177.6x |
| Current ratio | 0.0x | 0.0x | 15.0x | 9.4x | 3.8x |
| Quick ratio | 0.0x | 0.0x | 15.0x | 9.4x | 3.8x |
| Capital allocation | |||||
| Capex / revenue | β | 87.0% | β | β | β |
| Stock comp / revenue | β | 3,402.0% | 971.5% | β | 866.0% |
| Quality scores | |||||
| Piotroski F-score | β | β | 2.0 | β | β |
| Altman Z'' | β1,556.7 | β634.7 | β3.6 | β3.9 | β35.0 |
| Accruals ratio | β2,034.0% | β4,185.0% | 45.2% | β33.2% | β23.3% |
Source: SEC EDGAR XBRL filings (CIK 0001829247). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.